Epigenetic Silencing of ASPP1 confers 5 ‐FU resistance in Clear Cell Renal Cell Carcinoma by preventing p53 activation

In conclusion, our results suggest that ASPP1 silencing is one of dominate mechanisms in inhibiting wild type p53 in ccRCC. ASPP1, therefore, may be potentially used as a promising biomarker for prognosis and therapeutic intervention in ccRCC. This article is protected by copyright. All rights reserved. (Source: International Journal of Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from MedWorm via o.lakala70 on Inoreader http://ift.tt/2tlJwJt
via IFTTT